← All trials
NCT06055309
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2024
- Primary completion
- Feb 29, 2024
- Completion date
- Feb 29, 2024
- First posted
- Sep 26, 2023
- Last posted
- Nov 18, 2023
- Enrollment
- 5
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of ArkansasLead sponsor
- University of ArkansasOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.